Efficacy and liver function preservation with donafenib combined with transarterial chemoembolization in unresectable hepatocellular carcinoma: An ALBI grade analysis
The combination of donafenib and TACE demonstrates favorable hepatic function preservation while maintaining therapeutic efficacy. ALBI grade improvement is correlated with enhanced treatment response and survival outcomes, indicating potential synergistic benefits for tumor control and hepatic function preservation.
Authors
- Lujun Zhao
- Jinlin Du (ORCID: https://orcid.org/0000-0001-6117-3835)
- Li Yan (ORCID: https://orcid.org/0000-0002-2159-0009)
- Jingtao Zhong (ORCID: https://orcid.org/0000-0003-3686-9720)
- Yuanming Li (ORCID: https://orcid.org/0009-0000-9454-1614)
- Jinpeng Li
Institutions
- Tianjin Medical University Cancer Institute and Hospital (CN)
- People’s Hospital of Linqing (CN)
- Shangqiu First People's Hospital (CN)
- Hangzhou Hospital of Traditional Chinese Medicine (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-08-29
- DOI
- https://doi.org/10.3389/fonc.2025.1612477
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00